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Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-associated cryptococcal meningitis
(CM). Its use is hampered by toxicities that include electrolyte abnormalities, nephrotoxicity, and anemia. Protocols to minimize
toxicity are applied inconsistently. In a clinical trial cohort of AmBd-based CM induction treatment, a standardized protocol of
preemptive hydration and electrolyte supplementation was applied. Changes in blood counts, electrolyte levels, and creatinine
levels over 14 days were analyzed in relation to the AmBd dose, treatment duration (short course of 5 to 7 days or standard
course of 14 days), addition of flucytosine (5FC), and outcome. In the 368 patients studied, the hemoglobin levels dropped by a
mean of 1.5 g/dl (95% confidence interval [CI], 1.0 to 1.9 g/dl) following 7 days of AmBd and by a mean of 2.3 g/dl (95% CI, 1.1 to
3.6 g/dl) after 14 days. Serum creatinine levels increased by 37mol/liter (95% CI, 30 to 45mol/liter) by day 7 and by 49mol/
liter (95% CI, 35 to 64mol/liter) by day 14 of AmBd treatment. Overall, 33% of patients developed grade III/IV anemia, 5.6%
developed grade III hypokalemia, 9.5% had creatinine levels that exceeded 220mol, and 6% discontinued AmBd prematurely.
The addition of 5FC was associated with a slight increase in anemia but not neutropenia. Laboratory abnormalities stabilized or
reversed during the second week in patients on short-course induction. Grade III/IV anemia (adjusted odds ratio [aOR], 2.2;
95% CI, 1.1 to 4.3; P 0.028) and nephrotoxicity (aOR, 4.5; 95% CI, 1.8 to 11; P 0.001) were risk factors for 10-week mortality.
In summary, routine intravenous saline hydration and preemptive electrolyte replacement during AmBd-based induction regi-
mens for HIV-associated CMminimized the incidence of hypokalemia and nephrotoxicity. Anemia remained a concerning ad-
verse effect. The addition of flucytosine was not associated with increased neutropenia. Shorter AmBd courses were less toxic,
with rapid reversibility.
Amphotericin B (AmB) deoxycholate (AmBd) is a polyene an-tifungal that binds to ergosterol in the fungal cell membrane,
resulting in increased permeability and cell death (1) and binds to
cholesterol in mammalian cell membranes, partly explaining its
adverse effects of nephrotoxicity, electrolyte imbalance, and ane-
mia (1).
Less toxic lipid formulations of AmB, developed in the 1990s,
have now largely supplanted the use of the AmBd preparation for
the treatment of systemic mycoses in high-resource settings.
AmBd has been used to treat cryptococcal meningitis (CM) since
the pre-HIV era (2, 3). AmB exhibits concentration-dependent
killing (4), and successive randomized controlled trials used pro-
gressively increasing doses as induction therapy for HIV-associ-
ated CM, with or without flucytosine (5FC) or fluconazole as a
second agent (59). TreatmentwithAmBd at a dose of 1mg/kg of
body weight/day plus 5FC provided the best fungal clearance and
10-week survival rates in a recent phase III trial (10) and remains
the “gold standard” for the treatment of HIV-associated CM ac-
cording to IDSA and WHO guidelines (11, 12).
AmBd nephrotoxicity results from decreased renal blood flow
resulting in a reduced glomerular filtration rate and direct renal
tubular toxicity, causing potassium and magnesium losses (1).
Nephrotoxicity is cumulative and dose dependent although re-
versible (13, 14) and is reduced by preloading with saline, ade-
quate hydration, and electrolyte replacement (1519). Anemia
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results primarily from inhibition of renal erythropoietin produc-
tion, although hemolysis has been reported (20).
In resource-poor settings, facilities to prevent, monitor, and
manage AmBd toxicity are lacking. Fear of toxicities deters clini-
cians from using AmBd to treat CM. Instead, less effective but
widely available fluconazole monotherapy is used (21).
Since 2000, we have implemented a standardized protocol of
prehydration and preemptive electrolyte supplementation in clin-
ical trials of AmBd-based CM induction treatment in Asia and
Africa (14, 22–27), which is now included in WHO guidelines
(12).We present toxicity analyses of AmBd administered at a dose
in the currently recommended dose range (0.7 to 1mg/kg/day) for
treatment durations of 5 to 14 days, alone or combined with a
second antifungal, in a large combined cohort of patients with
HIV-associated CM managed in resource-limited settings. Our
aims were to characterize the association of AmBd dose and du-
ration, and the addition of 5FC, with the development of its com-
mon toxicities and to determine the relationship between toxicity
and mortality.
MATERIALS AND METHODS
Participants and procedures. The cohort consisted of adult HIV-in-
fected, antiretroviral therapy (ART)-naive patients with a first episode of
CM, enrolled in six phase II clinical trials carried out from 2002 to 2010 in
Asia and Africa (14, 23–27) (see Table S1 in the supplemental material).
All trials were approved by the Research Ethics Committees at each site
and at St. George’s University of London.
In trials 1 to 4, patients received standard (14-day) courses of AmBd,
and in studies 5 and 6, patients received shorter courses (7 days). Induc-
tion therapy differed in terms of the AmB dose (0.7 or 1mg/kg/day, dosed
according to actual body weight), choice of second and/or third drug, and
adjunctive gamma interferon. All patients on 5FC received 5FC orally,
except for 32 patients in the Thai study, who received intravenous (i.v.)
5FC as part of a pharmacokinetic substudy (28).
Management of toxicity. (i) Laboratorymonitoring.During the first
14 days, measurements of complete blood counts and urea, creatinine,
and electrolyte levels were performed for all patients on alternate days
(measurement of magnesium levels was available only in South Africa).
(ii) Electrolytes and renal impairment. Patients received daily prehy-
dration with 1 liter 0.9% (normal) saline with 20 mmol potassium chlo-
ride (KCl) before AmBd administration. Additional i.v. fluids were ad-
ministered at the study physicians’ discretion. Nephrotoxic drugs such as
aminoglycosides and nonsteroidal anti-inflammatory drugs (NSAIDs)
were avoided (premedication with paracetamol or chlorpheniramine was
allowed in the case of infusion reactions). If the creatinine level rose to 220
mol/liter (2.5 mg/dl), equivalent to grade III nephrotoxicity based on
Division of AIDS (DAIDS) criteria (creatinine increase of 1.9 to 3.4 times
the upper limit of normal [ULN]), the next AmBd dose was omitted, and
the patient was given additional i.v. fluids. The following day, if the cre-
atinine level was stable or improving, alternate daily dosing was instituted
at the same AmBd dose, with a return to daily dosing once the creatinine
level had normalized. If the creatinine level was still increasing, AmBd
treatment was stopped, and the patient was switched early to fluconazole,
adjusting the dose according to renal function (50% for a creatinine clear-
ance rate of 20 to 40 ml/min and 25% for a creatinine clearance rate of
20 ml/min). The flucytosine dose interval was extended to a 12-h inter-
val if the creatinine clearance rate decreased to 20 to 40 ml/min and once
daily if the creatinine clearance rate was20ml/min. In all South African
trials, patients received oral electrolyte supplementation with 2 tablets of
potassium chloride (Slow-K, 600mg [8mmol K/tablet]) twice daily and 2
tablets of magnesium chloride (Slow-Mag, 535 mg [5.33 mmol Mg/tab-
let]) once daily, with additional i.v. or oral supplementation as required.
At other sites, additional i.v. or oral potassium was administered accord-
ing to laboratory results.
(iii) Bonemarrow toxicity.Due to limited blood product availability,
there was no hemoglobin (Hb) threshold for transfusion; this was done at
the study sites’ discretion. Flucytosine treatment was stopped if platelet
numbers dropped to 50  109 platelets/ml or if neutrophil numbers
dropped to0.5 109 neutrophils/liter.
Statistical analyses.Weexplored changes inHb levels, neutrophil and
platelet numbers, creatinine levels, K levels, and Mg levels over a 14-day
period following the start of AmBd-based treatment. For each measure,
we used LOESS (locally weighted scatterplot smoothing) to estimate the
mean value as a function of the number of days after treatment initiation.
Linear regression models were constructed to examine the effects of
the AmB dose (0.7 or 1mg/kg/day) and treatment duration (5 to 7 days or
14 days) on changes in Hb, K, and creatinine levels from baseline to days
7 and 14; peak creatinine levels; andHbnadir. Sex and treatmentwith 5FC
were included as potential confounders in Hb analyses. Baseline imbal-
ances between groups were accounted for by using a “change from base-
line” analysis rather than adjusting for baseline (with the exception of
peak and nadir values).
Logistic regression models examined associations between protocol-
predefined nephrotoxicity, DAIDS grade III hypokalemia (K level of 2 to
2.4 mmol/liter or meq/liter), grade III (Hb level of 6.5 to 7.4 g/dl) and
grade IV (Hb level of 6.5 g/dl) anemia, and mortality at 2 and 10
weeks, with adjustments for baseline values (Hb, creatinine, and K),
patient weight in the nephrotoxicity analysis, and the established prog-
nostic markers baseline fungal burden, altered mental status, and CD4
cell count (29).
Given the pooling of data across studies, clustering by study in both
the linear and logistic regression models was accounted for by including
“study” as a random-effect term.
Data were analyzed by using Stata, v12.0 (StataCorp, TX, USA).
RESULTS
A total of 368 (52% male) patients were included: 64 (17%) were
Thai, 298 (81%) were black African, and 3 (1%) were of mixed
race. The median age was 33 years (interquartile range [IQR], 29
to 38 years), and the CD4 count was 25 cells/l (IQR, 10 to 55
cells/l). Changes from baseline (pretreatment) are shown in Ta-
ble 1, and LOESS curves are shown in Fig. 1 and 2.
From a mean baseline of 11 g/dl, the mean overall drops in
hemoglobin levels were 1.5 g/dl (12%) by day 7 and 2.3 g/dl (20%)
by day 14. With preemptive supplementation, potassium values
remained stable over time (see Fig. S1a in the supplemental mate-
rial). The mean change in creatinine levels from baseline values
were 37 mol/liter (95% CI, 30 to 45 mol/liter) at day 7 and
49 mol/liter (95% CI, 35 to 64 mol/liter) at day 14.
Incidence of serious toxicity.Grade III/IV anemia (Hb level of
7.5 g/dl) developed in 112 patients (33%).
Fifty-nine patients (18%) developed grade IV anemia (Hb level
of 6.5 g/dl). Women had higher incidences of grade III (54%
versus 14%) and grade IV (31% versus 5%) anemia (P  0.001)
due to sex differences in baseline values rather than differences in
on-treatment change (day 14 drop in Hb level of 2.14 g/dl for
males versus 2.21 g/dl for females; P 0.92) (Fig. 1c). In the South
African trials, which collected transfusion data, 12 of 304 patients
(4%) received blood transfusions, constituting only 20% of pa-
tients with grade IV anemia.
Sixteen of 284 patients (5.6%) developed grade III hypokale-
mia (K level of2.5mmol/liter), 5 in the first week of treatment.
Three patients (1.1% of the cohort) developed grade IV hypoka-
lemia (K level of2 mmol/liter): 2 on day 11 and 1 on day 12 of
treatment. In the South African trials using preemptive oral in
addition to i.v. K supplementations, the change in the potassium
level from baseline differed significantly from those in trials not
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using oral K (meanday 7 change in theK level of0.39mmol/liter
[95% CI, 0.24 to 0.54 mmol/liter] versus0.17 mmol/liter [95%
CI,0.47 to0.12 mmol/liter]; P 0.001 by t test), with a lower
incidence of grade III hypokalemia (4.2% versus 9.7%; P 0.08).
Thirty-three patients (9.5%) exceeded the protocol-defined
nephrotoxicity threshold (creatinine level of220mol/liter). In
the South African trials using standard-course AmBd (n  234),
15 patients (6.4%) discontinued AmBd early due to nephrotoxic-
TABLE 1 Changes in laboratory parameters from baseline values over 1 and 2 weeks of AmBd treatmenta
Laboratory parameter
Mean value (95% CI)
Baseline value
Absolute change to
day 7
% change to
day 7
Absolute change to
day 14b
% change to
day 14b
Hemoglobin level (g/dl) 11 (10.4, 11.6) 1.5 (1.9,1) 12 (16,9) 2.3 (3.6,1.1) 20 (32,8)
Creatinine level (mol/liter) 77 (68,87) 37 (30, 45) 52 (43, 62) 49 (35, 64) 73 (53, 93)
Potassium level (mmol/liter) 3.9 (3.8, 4.0) 0.2 (0.0, 0.5) 9 (3, 15) 0.1 (0.1, 0.3) 6 (1, 11)
Magnesium level (mmol/liter) 0.7 (0.6, 0.8) 0.07 (0.12,0.02) 1(7, 5) 0.15 (0.2,0.1) 10 (33,13)
Neutrophil count (109/liter) 3.5 (2.2, 4.9) 0.1 (0.4, 0.0.1) 8 (0.9, 14) 0.3 (0.5, 0.0) 8 (3, 20)
a Values shown are means with 95% CIs adjusted for study-level clustering.
b Changes from baseline to day 14 are calculated only for patients enrolled in studies of standard-course AmBd treatment(1–4).
FIG 1 Individual data points and fitted LOESS curves for hemoglobin values over the first 14 days of antifungal therapy. (a) All patients receiving 14 days of
AmB-based induction therapy. (b) Plot by AmB duration (short-course versus standard treatment). (c) Plot by sex. The broken line indicates a DAIDS grade IV
adverse-event threshold of 6.5 g/dl.
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ity, at amedian of 11 days (range, 5 to 13 days). In the short-course
trials (n  70), 4 patients (5.7%) stopped treatment early (all in
the 7-day study), 3 of whom omitted the final day only.
Toxicity by AmB dose and duration. There was a greater ab-
solute drop in the Hb level at days 7 and 14 in patients receiving
the higher AmBd dose and in those receiving standard treatment
versus short-course treatment, although differences were nonsig-
nificant (see Table S2 in the supplemental material). Patients re-
ceiving shorter courses had higher nadir Hb levels (mean of 9.5
versus 8.3 g/dl), even after adjustment for sex and 5FC treatment
(P 0.033).
There was less renal impairment in those receiving the 0.7-
mg/kg AmBd dose, with mean increases in creatinine levels of 28
versus 41 mol/liter at day 7 (P  0.02) and 42 versus 53 mol/
liter at day 14 (P 0.09). The mean creatinine level peaked at 127
versus 145 mol/liter (P  0.04), remaining significant upon
multivariable analysis (adjustedmean difference of 13mol/liter;
P 0.04). Despite similarities in peak creatinine levels, the change
in creatinine levels to day 14 was less in patients receiving short-
course than in those receiving standard treatment (mean increase
of 17 versus 49mol/liter; P 0.001) (see Table S2 in the supple-
mental material).
Reversibility. TheHb level stabilized and started to increase in
the second week in the short-course group after AmBd treatment
was stopped, while it continued to decline in the standard-course
group (mean change at week 2 of 0.12 versus 0.93 g/dl; P 
0.01) (Fig. 1b).
Renal impairment in the short-course group resolved in
week 2 following cessation of AmBd, with the creatinine levels
continuing to rise in the standard-course group (mean
FIG 2 Individual data points and fitted LOESS curves for creatinine values over the first 14 days of antifungal therapy. (a) All patients receiving 14 days of
AmB-based induction therapy. (b) Plot by AmB dose (0.7 versus 1 mg/kg/day). (c) Plot by AmB duration (short-course versus standard treatment). The broken
line indicates a threshold of 220 mol/liter (protocol definition of nephrotoxicity).
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change at week 2 of 28 versus 14 mol/liter; P  0.001)
(Fig. 2c).
Potassium. There was no significant association of AmB dose
or duration with changes in potassium levels (data not shown).
The LOESS curves of changes in potassium levels (see Fig. S1 in the
supplementalmaterial) show a dip inK levels during days 8 to 10
in the short-course trials, after AmBd administration and K sup-
plementation were stopped, which is supportive of ongoing po-
tassium wasting (30).
Incidences of grade III/IV hypomagnesemia, neutropenia, and
thrombocytopenia and associations with the use of 5FC are de-
scribed in the supplemental material.
Associationof toxicitywith 2- and10-weekoutcomes.Devel-
opment of nephrotoxicity (creatinine level of 220 mol/liter)
was associated with 2-week mortality (Table 2); however, this was
no longer significant in the adjustedmodel (2-week adjusted odds
ratio [aOR], 2.9; 95% CI, 0.6 to 12.7; P  0.17). The association
between nephrotoxicity and 10-week mortality remained signifi-
cant following adjustment for the baseline creatinine level, weight,
CD4 count, fungal burden, altered mental status, and study (10-
week aOR, 4.5; 95% CI, 1.8 to 11; P 0.001) (Table 2).
Severe anemia (grade III/IV) was a significant risk factor for
10-week mortality following adjustment for the baseline Hb level,
CD4 count, fungal burden, alteredmental status, and study (aOR,
2.2; 95% CI, 1.1 to 4.3; P 0.028) (Table 2).
Development of grade III hypokalemia (K level of 2.5
mmol/liter) was not associated with mortality (Table 2).
DISCUSSION
This analysis of 368 patients treated with AmBd-based induction
regimens in resource-poor settings represents the largest reported
toxicity analysis of treatment for HIV-associated CM.
Trials reporting the toxicity of AmBd at the recommended 0.7-
to 1-mg/kg/day doses for HIV-associated CM include 6 trials in
high-income settings (6, 8, 31–34) and 8 trials in low-income set-
tings in Asia and Africa (9, 10, 35–40) (see Table S3 in the supple-
mental material). Six trials reported routine use of saline preload-
ing, and one reported preemptive electrolyte replacement (41).
Definitions of nephrotoxicity varied. The incidence of grade III
nephrotoxicity (or equivalent) was 20 to 33% in older trials with-
out routine fluid preloading (8, 32, 36), compared to 2 to 11% in
our study and in more recent trials using saline preloading (10,
39). Six percent of our patients discontinued treatment early, usu-
ally 1 to 2 days before completion, in comparison to up to 53% in
previously reported trials.
AmBd nephrotoxicity is cumulative (42): in our patients, the
creatinine level rose by a mean of 52% by day 7 and by a mean of
73%by day 14. Although nephrotoxicity was greater for the 1-mg/
kg/day dose, this translated into a mean difference in the peak
creatinine level of 13 mol/liter, which is of minor clinical signif-
icance and should not deter clinicians from using the more-fun-
gicidal, higher dose.
The long terminal half-life of AmBd (up to 2 weeks) (4) pro-
vides ongoing fungicidal activity after drug administration is
stopped (25, 27). These data demonstrate better tolerability of 5-
to 7-day regimens, with less nephrotoxicity and reversibility and
with creatinine levels returning almost to baseline 1 week after
discontinuation of short-course AmBd treatment. Ongoing elec-
trolyte losses following AmBd discontinuation mean that supple-
mentation and monitoring are needed for several more days, an T
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important implementation issue, as stable patients are usually dis-
charged following discontinuation of intravenous therapy. Short-
course regimens minimize toxicity while potentially maintaining
efficacy as well as reducing costs of hospitalization, intravenous
administration, and laboratorymonitoring. A phase III trial com-
paring short-course to standard AmBd regimens is under way
in Africa (ACTA, ISRCTN Registry number 45035509). Admin-
istration of fewer, higher doses of liposomal preparations may be
an alternative (AmBition-CM, ISRCTN Registry number
10248064).
The reported incidences of hypokalemia (7 studies, with vari-
able definitions) (see Table S3 in the supplementalmaterial) range
from1 to 56%. In this cohort, with routine preemptive supple-
mentation with 20 mmol KCl (and supplemental oral potassium
in South Africa), potassium levels changed little over 14 days. In a
recent large Vietnamese trial (10), 18% of patients developed
grade III hypokalemia, as opposed to only 6% in our cohort and
9% in a Ugandan cohort using preemptive replacement (41).
These data supportWHO recommendations for preemptive daily
supplementation with 20mmol KCl i.v., with additional oral sup-
plementation (12).
Despite oral supplementation, hypomagnesemia was much
more common than hypokalemia in our cohort. Unfortunately,
magnesium levels were not measured at study sites where routine
supplementationwas not given, for comparison. The lack of avail-
ability of magnesium monitoring or oral replacement prepara-
tions (magnesium chloride or glycerophosphate) is a problem. i.v.
magnesium (usually stocked for preeclampsia) can be considered
for patients with severe deficiency or those remaining hypokalemic
despite potassium replacement (12).
Rates of anemia reported in 8 studies (variable definitions) (see
Table S3 in the supplemental material) ranged from 37 to 44%.
Two trials reported an average drop in the Hb level of 1.5 to 2.5
g/dl; in one trial, 59% of patients received transfusions (34, 38).
Despite the development of grade IV anemia (Hb level of 6.5
g/dl) in 16% of our cohort, with a mean decrease in hemoglobin
levels of 2.3 g/dl over 14 days, only 4% of patients received trans-
fusions, reflecting the scarcity of blood for transfusion in Africa.
Severe AmBd-induced anemia is potentially life-threatening in
such settings, given the low baseline Hb levels and the current lack
of validated preventative interventions.
The addition of oral 5FC to AmBd treatment did not result in
clinically significant excess toxicity in our cohort, with a slightly
greater drop in the hemoglobin level but no increases in rates of
neutropenia or thrombocytopenia, an important observation
given that this combination remains the recommended CM in-
duction regimen.
Development of nephrotoxicity and severe anemia were inde-
pendent risk factors for mortality, with odds of dying at 10 weeks
being increased 2-fold for patients with a decrease of the hemo-
globin level of7.5 g/dl and4-fold in those with an increase of
the creatinine level of220 mol/liter. Using these cutoffs, ane-
mia was3 timesmore common than nephrotoxicity. The lack of
an association between hypokalemia andmortality is likely related
to routine preemptive potassium replacement.
A limitation of this study is the pooling of data from multiple
cohorts treated with different AmBd-based combination regi-
mens from four countries on two continents over an 8-year pe-
riod. Although toxicity management was uniform across trial
sites, theremay have been heterogeneities in clinicalmanagement.
To address this, we adjusted for potential variable-specific and
outcome-related confounders in themultivariate analyses and in-
cluded an additional study variable to try to account for any resid-
ual confounding due to unmeasured effects related to temporal or
site-specific differences.
Findings from this large cohort of patients treated in resource-
poor settings demonstrate that with appropriate laboratory mon-
itoring, it is possible to implement the most fungicidal AmBd-
based induction treatment regimens for HIV-associated CM by
using a standardized protocol for preemptive toxicity manage-
ment. Hypokalemia was minimized, and nephrotoxicity occurred
in 10% of patients. Anemia remains a concerning side effect.
Shorter courses of AmBd are less toxic, with rapid reversibility.
The implementation of standardized protocols for preemptive
toxicity management is a priority in countries with a high HIV
prevalence to maximize the benefits of a drug that is likely to
remain a cornerstone of CM treatment for many years to come.
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